Evidence map›Paper›PMID 40042304›Full record

ArticleAntimicrobial agents and chemotherapy2025

Pharmacokinetics of islatravir in participants with moderate hepatic impairment.

Randolph P Matthews, Munjal Patel, Wen Liu, Yang Liu, Juan C Rondón, Ryan C Vargo, S Aubrey Stoch, Marian Iwamoto

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04515641 (An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04515641 phase1completednot on this map

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Islatravir (MK-8591) in Participants With Moderate Hepatic Impairment

TypeinterventionalSponsorMerck Sharp & Dohme LLCRan2020 to 2021Enrolled12ConditionsHuman Immunodeficiency Virus (HIV) InfectionArmsIslatravir
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Randolph P MatthewsMerck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0002-8403-267X
Munjal PatelMerck & Co., Inc., Rahway, New Jersey, USA.ORCID 0000-0001-6892-0899
Wen LiuMerck & Co., Inc., Rahway, New Jersey, USA.
Yang LiuMerck & Co., Inc., Rahway, New Jersey, USA.
Juan C RondónClinical Pharmacology of Miami, Hialeah, Florida, USA.
Ryan C VargoMerck & Co., Inc., Rahway, New Jersey, USA.
S Aubrey StochMerck & Co., Inc., Rahway, New Jersey, USA.
Marian IwamotoMerck & Co., Inc., Rahway, New Jersey, USA.

Funding

Merck
6 · The paper itself

Abstract

Islatravir (ISL) is a nucleoside reverse transcriptase translocation inhibitor in development for the treatment of HIV-1 infection. People living with HIV are at risk of liver disease. ISL is metabolized by adenosine deaminase (ADA), which is expressed in the liver; thus, ISL pharmacokinetics (PK) may be affected by hepatic impairment. This study evaluated the effect of moderate hepatic impairment on ISL PK. This nonrandomized, open-label, phase 1 study (MK-8591-030) evaluated the effects of a single oral dose of ISL 60 mg in HIV-seronegative adults with moderate hepatic insufficiency (

Indexed as

Anti-HIV AgentsHepatic InsufficiencyHeterocyclic Compounds, 4 or More RingsHIV InfectionsAdultArea Under CurveDeoxyadenosinesFemaleHumansLeukocytes, MononuclearMaleMiddle AgedNitrilesAnti-HIV AgentsDeoxyadenosinesHeterocyclic Compounds, 4 or More RingsislatravirNitrileshepatic impairmenthuman immunodeficiency virusislatravirliver diseasepharmacokinetics

Identifiers

PMID40042304
PMCPMC11963540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.